{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T16:18:10Z","timestamp":1793981890513,"version":"4.8.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circ: Cardiovascular Quality and Outcomes"],"published-print":{"date-parts":[[2012,9]]},"abstract":"<jats:sec>\n            <jats:title>Background\u2014<\/jats:title>\n            <jats:p>Elderly patients with acute coronary syndrome are at high risk of recurrent ischemic events and death, and for both antithrombotic therapy and catheter-based complications. This prespecified analysis investigates the effect and treatment-related complications of ticagrelor versus clopidogrel in elderly patients (\u226575 years of age) with acute coronary syndrome compared with those &lt;75 years of age.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods and Results\u2014<\/jats:title>\n            <jats:p>\n              The association between age and the primary composite outcome, as well as major bleeding were evaluated in the PLATelet inhibition and patient Outcomes (PLATO) trial using Cox proportional hazards. Similar models were used to evaluate the interaction of age with treatment effects. Hazard ratios were adjusted for baseline characteristics. The clinical benefit of ticagrelor over clopidogrel was not significantly different between patients aged \u226575 years of age (n=2878) and those &lt;75 years of age (n=15 744) with respect to the composite of cardiovascular death, myocardial infarction, or stroke (interaction\n              <jats:italic>P<\/jats:italic>\n              =0.56), myocardial infarction (\n              <jats:italic>P<\/jats:italic>\n              =0.33), cardiovascular death (\n              <jats:italic>P<\/jats:italic>\n              =0.47), definite stent thrombosis (\n              <jats:italic>P<\/jats:italic>\n              =0.81), or all-cause mortality (\n              <jats:italic>P<\/jats:italic>\n              =0.76). No increase in PLATO-defined overall major bleeding with ticagrelor versus clopidogrel was observed in patients aged \u226575 years (hazard ratio, 1.02; 95% confidence interval, 0.82\u20131.27) or patients aged &lt;75 years (hazard ratio, 1.04; 95% confidence interval, 0.94\u20131.15). Dyspnea and ventricular pauses were more common during ticagrelor than clopidogrel treatment, with no evidence of an age-by-treatment interaction.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions\u2014<\/jats:title>\n            <jats:p>The significant clinical benefit and overall safety of ticagrelor compared with clopidogrel in acute coronary syndrome patients in the PLATO cohort were not found to depend on age.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Clinical Trial Registration\u2014<\/jats:title>\n            <jats:p>\n              URL:\n              <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/clinicaltrials.gov\">http:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n              . Unique identifier: NCT00391872.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/circoutcomes.111.964395","type":"journal-article","created":{"date-parts":[[2012,9,18]],"date-time":"2012-09-18T20:34:12Z","timestamp":1348000452000},"page":"680-688","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":205,"title":["Ticagrelor Versus Clopidogrel in Elderly Patients With Acute Coronary Syndromes"],"prefix":"10.1161","volume":"5","author":[{"given":"Steen","family":"Husted","sequence":"first","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"James","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard C.","family":"Becker","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay","family":"Horrow","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hugo","family":"Katus","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert F.","family":"Storey","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher P.","family":"Cannon","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magda","family":"Heras","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renato D.","family":"Lopes","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao","family":"Morais","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth W.","family":"Mahaffey","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard G.","family":"Bach","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Wojdyla","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars","family":"Wallentin","sequence":"additional","affiliation":[{"name":"From the Department of Cardiology, \u00c5rhus University Hospital, \u00c5rhus, Denmark (S.H.); Uppsala Clinical Research Center, Uppsala University, Uppsala, Sweden (S.J., L.W.); Duke Clinical Research Institute, Durham, NC (R.C.B., R.D.L., K.W.M., D.W.); AstraZeneca R&amp;D, Wilmington, DE (J.H.); Medizinische Klinik, Universit\u00e4tsklinikum Heidelberg, Germany (H.K.); Department of Cardiovascular Science, University of Sheffield, Sheffield, UK (R.F.S.); TIMI Study Group, Brigham and Women\u2019s Hospital, Boston,..."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the PLATO study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.101.22.2557"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.291.22.2727"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.163.19.2345"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2009.06.021"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0b013e328343e9ce"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cger.2007.01.004"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S3035"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2004.06.003"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.181940"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.5.1390"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm194"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.09.076"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1161\/strokeaha.108.526988"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-141-10-200411160-00005"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)80089-3"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.0000081659.72985.a8"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.109.192663"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31820f2f3e"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.182615"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.107.182616"},{"key":"e_1_3_4_22_2","first-page":"101","article-title":"Trends in aging--United States and worldwide.","volume":"52","author":"Centers for Disease Control (CDC).","year":"2003","unstructured":"Centers for Disease Control (CDC). Trends in aging--United States and worldwide. MMWR Morb Mortal Wkly Rep. 2003;52:101\u2013104.","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2009.01.003"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0904327"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0706482"},{"key":"e_1_3_4_26_2","unstructured":"U.S. Food and Drug Administration. Cardiovascular and Renal Drug Advisory Committee briefing document: Questions prasugrel for ACS. February 3 2009. Available at: http:\/\/www.fda.gov\/ohrms\/dockets\/ac\/09\/briefing\/2009-4412b1-01-FDA.pdf. Accessed September 28 2011."},{"key":"e_1_3_4_27_2","unstructured":"European Medicines Agency. European Public Assessment Report (EPAR) Efient prasugrel. 2009. Available at: http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000984\/WC500021971.pdf. Accessed September 28 2011."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010746"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(01)05701-4"}],"container-title":["Circulation: Cardiovascular Quality and Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCOUTCOMES.111.964395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T02:44:47Z","timestamp":1715568287000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCOUTCOMES.111.964395"}},"subtitle":["A Substudy From the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial"],"short-title":[],"issued":{"date-parts":[[2012,9]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["10.1161\/CIRCOUTCOMES.111.964395"],"URL":"https:\/\/doi.org\/10.1161\/circoutcomes.111.964395","relation":{},"ISSN":["1941-7713","1941-7705"],"issn-type":[{"value":"1941-7713","type":"print"},{"value":"1941-7705","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,9]]},"assertion":[{"value":"2011-10-19","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-07-25","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2012-09-01","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}